CERo Therapeutics reports $3.3M preliminary cash; appoints Shami Patel to board

CERO THERAPEUTICS HOLDINGS, INC.

Preliminary unaudited cash and cash equivalents as of Sept 30, 2024 were approximately $3.3 million.
Board appointed Shami Patel as Class III director effective Oct 11, 2024, filling vacancy from Dr. Corey's resignation.
Cash estimate is preliminary and subject to change upon completion of quarter-end close; no audit performed.
Patel is a Managing Director at Launchpad Capital with extensive SPAC and financial services experience.

item 2.02 item 5.02 item 7.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Shami Patel

Class III Director

CERO · CERO THERAPEUTICS HOLDINGS, INC.

Effective: 2024-10-11
Filed: October 11, 2024, 7:59 PM ET

On October 9, 2024, the Board of Directors (the “ Board ”) of the Company appointed Shami Patel to the Board as a Class III director, effective October 11, 2024, to fill the vacancy created by Dr. Corey’s resignation

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Shami Patel was appointed as Class III Director at CERO THERAPEUTICS HOLDINGS, INC..

Action: appointed
Role: Class III Director

Exact text from the filing

On October 9, 2024, the Board of Directors (the “ Board ”) of the Company appointed Shami Patel to the Board as a Class III director, effective October 11, 2024, to fill the vacancy created by Dr. Corey’s resignation

View on SEC.gov

CERO THERAPEUTICS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-24-087267

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.